PMVP Logo

PMV Pharmaceuticals, Inc. (PMVP) 

NASDAQ
Market Cap
$83.98M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
673 of 776
Rank in Industry
364 of 433

Largest Insider Buys in Sector

PMVP Stock Price History Chart

PMVP Stock Performance

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and …

Insider Activity of PMV Pharmaceuticals, Inc.

Over the last 12 months, insiders at PMV Pharmaceuticals, Inc. have bought $0 and sold $210,963 worth of PMV Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at PMV Pharmaceuticals, Inc. have bought $106.6M and sold $18.57M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,900,000 shares for transaction amount of $34.2M was made by RA CAPITAL MANAGEMENT, L.P. (10 percent owner) on 2020‑09‑29.

List of Insider Buy and Sell Transactions, PMV Pharmaceuticals, Inc.

2024-09-11SaleChief Development Officer
7,218
0.0141%
$1.50$10,853-0.90%
2024-09-11SaleChief Financial Officer
2,891
0.0057%
$1.50$4,347-0.90%
2023-11-22Sale10 percent owner
87,786
0.1816%
$2.23$195,763-23.70%
2023-09-15SaleChief Medical Officer
6,291
0.0128%
$6.62$41,646-73.47%
2023-09-15SaleChief Development Officer
4,104
0.0084%
$6.62$27,168-73.47%
2022-05-26Sale
26,253
0.0695%
$15.93$418,210-25.36%
2022-03-29Sale
365,000
0.7867%
$21.52$7.85M-45.86%
2021-10-06Saledirector
800
0.0019%
$30.15$24,120-43.26%
2021-10-04Saledirector
100
0.0002%
$30.08$3,008-43.75%
2021-10-01Saledirector
11,541
0.0255%
$30.10$347,384-46.13%
2021-09-30Saledirector
2,978
0.0066%
$30.03$89,429-45.30%
2021-09-29Saledirector
5,708
0.0127%
$30.04$171,468-45.33%
2021-09-27Saledirector
1,753
0.004%
$30.11$52,783-44.51%
2021-09-22Saledirector
100
0.0002%
$30.00$3,000-41.71%
2021-09-22Saledirector
3,500
0.0082%
$30.00$105,000-41.71%
2021-09-17Saledirector
711
0.0016%
$30.03$21,351-42.79%
2021-09-13Saledirector
13,272
0.0311%
$30.20$400,814-40.29%
2021-09-10Saledirector
43,227
0.0948%
$30.51$1.32M-44.58%
2021-09-09Saledirector
14,329
0.0332%
$30.31$434,312-40.96%
2021-09-09SaleChief Medical Officer
100
0.0002%
$30.25$3,025-40.96%

Insider Historical Profitability

<0.0001%
ORBIMED ADVISORS LLC10 percent owner
0
0%
$1.6311<0.0001%
RA CAPITAL MANAGEMENT, L.P.10 percent owner
1710265
3.3196%
$1.6310<0.0001%
Boxer Capital, LLC
950000
1.844%
$1.6310<0.0001%
Thompson Peter A.
475000
0.922%
$1.6310<0.0001%
ORONSKY ARNOLD L
55555
0.1078%
$1.6310<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
OrbiMed$11.01M12.596.48M0%+$00.09
Arrowmark Colorado Holdings Llc$5.44M6.223.2M+17.86%+$823,842.070.01
BlackRock$5.29M6.053.11M-3.7%-$203,129.59<0.0001
Euclidean Capital Llc$4.47M5.112.63M0%+$00.58
The Vanguard Group$4.17M4.772.45M+1.95%+$79,566.81<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.